Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy

[1]  C. Overall,et al.  Towards third generation matrix metalloproteinase inhibitors for cancer therapy , 2006, British Journal of Cancer.

[2]  A. Ben-Baruch.  Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators. , 2006, Seminars in cancer biology.

[3]  A. Gansmuller,et al.  Stromelysin-3 is a potent negative regulator of adipogenesis participating to cancer cell-adipocyte interaction/crosstalk at the tumor invasive front. , 2005, Cancer research.

[4]  J. Tanne.  Merck faces ongoing claims after Texan ruling on rofecoxib , 2005, BMJ : British Medical Journal.

[5]  C. McCaig,et al.  Insulin-like growth factor binding protein-5 is a target of matrix metalloproteinase-7: implications for epithelial-mesenchymal signaling. , 2005, Cancer research.

[6]  J. Hamon,et al.  Structure-based design and synthesis of novel non-zinc chelating MMP-12 inhibitors. , 2005, Bioorganic & medicinal chemistry letters.

[7]  J. Peterse,et al.  Breast cancer metastasis: markers and models , 2005, Nature Reviews Cancer.

[8]  Andy J. Minn,et al.  Genes that mediate breast cancer metastasis to lung , 2005, Nature.

[9]  D. Edwards,et al.  Metalloproteinases and their inhibitors in tumor angiogenesis , 2005, International journal of cancer.

[10]  D. Albertson,et al.  Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability , 2005, Nature.

[11]  B. Nielsen,et al.  Intracellular collagen degradation mediated by uPARAP/Endo180 is a major pathway of extracellular matrix turnover during malignancy , 2005, The Journal of cell biology.

[12]  R. Ball,et al.  Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues , 2005, British Journal of Cancer.

[13]  A. Krüger,et al.  Antimetastatic activity of a novel mechanism-based gelatinase inhibitor. , 2005, Cancer research.

[14]  Karla K Kopec,et al.  Target identification and validation in drug discovery: the role of proteomics. , 2005, Biochemical pharmacology.

[15]  Ivano Bertini,et al.  Conformational variability of matrix metalloproteinases: beyond a single 3D structure. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[16]  B. Psaty,et al.  COX-2 inhibitors--lessons in drug safety. , 2005, The New England journal of medicine.

[17]  P Cuniasse,et al.  Future challenges facing the development of specific active-site-directed synthetic inhibitors of MMPs. , 2005, Biochimie.

[18]  Wenmei Li,et al.  Matrix metalloproteinase 11 depletion inhibits cell proliferation in gastric cancer cells. , 2005, Biochemical and biophysical research communications.

[19]  W. Gerald,et al.  Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. , 2005, The Journal of clinical investigation.

[20]  C. Overall.  Dilating the degradome: matrix metalloproteinase 2 (MMP-2) cuts to the heart of the matter. , 2004, The Biochemical journal.

[21]  R. Epstein.  The CXCL12–CXCR4 chemotactic pathway as a target of adjuvant breast cancer therapies , 2004, Nature Reviews Cancer.

[22]  A. Berner,et al.  Altered Expression of Metastasis-Associated and Regulatory Molecules in Effusions from Breast Cancer Patients , 2004, Clinical Cancer Research.

[23]  N. Davies,et al.  COX-2 selective inhibitors cardiac toxicity: getting to the heart of the matter. , 2004, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[24]  Eric J Topol,et al.  Failing the public health--rofecoxib, Merck, and the FDA. , 2004, The New England journal of medicine.

[25]  C. Overall,et al.  Characterization of the Distinct Collagen Binding, Helicase and Cleavage Mechanisms of Matrix Metalloproteinase 2 and 14 (Gelatinase A and MT1-MMP) , 2004, Journal of Biological Chemistry.

[26]  L. Matrisian,et al.  A Protective Role for Matrix Metalloproteinase-3 in Squamous Cell Carcinoma , 2004, Cancer Research.

[27]  Sophie Perrier,et al.  Crystal structures of novel non-peptidic, non-zinc chelating inhibitors bound to MMP-12. , 2004, Journal of molecular biology.

[28]  William C. Parks,et al.  Matrix metalloproteinases as modulators of inflammation and innate immunity , 2004, Nature Reviews Immunology.

[29]  Nasreen S Jessani,et al.  Activity-based probes for the proteomic profiling of metalloproteases. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[30]  F. Balkwill.  Cancer and the chemokine network , 2004, Nature Reviews Cancer.

[31]  A. Noël,et al.  Diet-Induced Obesity and Reduced Skin Cancer Susceptibility in Matrix Metalloproteinase 19-Deficient Mice , 2004, Molecular and Cellular Biology.

[32]  M. Stack,et al.  Membrane protease proteomics: Isotope-coded affinity tag MS identification of undescribed MT1-matrix metalloproteinase substrates. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[33]  Soumyendu Raha,et al.  Similarity of Binding Sites of Human Matrix Metalloproteinases*[boxs] , 2004, Journal of Biological Chemistry.

[34]  R. Ball,et al.  Dysregulated Expression of Adamalysin-Thrombospondin Genes in Human Breast Carcinoma , 2004, Clinical Cancer Research.

[35]  B. Shalmon,et al.  The tumor microenvironment: CXCR4 is associated with distinct protein expression patterns in neuroblastoma cells. , 2004, Immunology letters.

[36]  D. Tarin,et al.  Altered Metastatic Behavior of Human Breast Cancer Cells after Experimental Manipulation of Matrix Metalloproteinase 8 Gene Expression , 2004, Cancer Research.

[37]  F. Beau,et al.  Evaluation of P1'-diversified phosphinic peptides leads to the development of highly selective inhibitors of MMP-11. , 2004, Journal of medicinal chemistry.

[38]  M. Waltham,et al.  Pro-Matrix Metalloproteinase-2 Transfection Increases Orthotopic Primary Growth and Experimental Metastasis of MDA-MB-231 Human Breast Cancer Cells in Nude Mice , 2004, Cancer Research.

[39]  X. Puente,et al.  Protease degradomics: mass spectrometry discovery of protease substrates and the CLIP-CHIP, a dedicated DNA microarray of all human proteases and inhibitors , 2004, Biological chemistry.

[40]  B. Shalmon,et al.  Progression of mouse mammary tumors: MCP‐1‐TNFα cross‐regulatory pathway and clonal expression of promalignancy and antimalignancy factors , 2003, International journal of cancer.

[41]  C. Overall,et al.  HIV-induced metalloproteinase processing of the chemokine stromal cell derived factor-1 causes neurodegeneration , 2003, Nature Neuroscience.

[42]  C. López-Otín,et al.  Loss of collagenase-2 confers increased skin tumor susceptibility to male mice , 2003, Nature Genetics.

[43]  X. Puente,et al.  Human and mouse proteases: a comparative genomic approach , 2003, Nature Reviews Genetics.

[44]  V. Quaranta,et al.  Tales from the crypt[ic] sites of the extracellular matrix. , 2003, Trends in cell biology.

[45]  Bart Barlogie,et al.  A phase 2 study of bortezomib in relapsed, refractory myeloma. , 2003, The New England journal of medicine.

[46]  B. Fingleton.  Matrix metalloproteinase inhibitors for cancer therapy: the current situation and future prospects , 2003, Expert opinion on therapeutic targets.

[47]  C. Cordon-Cardo,et al.  A multigenic program mediating breast cancer metastasis to bone. , 2003, Cancer cell.

[48]  I. Fidler,et al.  The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited , 2003, Nature Reviews Cancer.

[49]  Seth M. Cohen,et al.  Examination of novel zinc-binding groups for use in matrix metalloproteinase inhibitors. , 2003, Inorganic chemistry.

[50]  L. Matrisian,et al.  Cooperative effects of matrix metalloproteinase and cyclooxygenase-2 inhibition on intestinal adenoma reduction , 2003, British Journal of Cancer.

[51]  T. Salo,et al.  Matrix metalloproteinases process the laminin-5 γ2-chain and regulate epithelial cell migration , 2003 .

[52]  Kenneth M. Yamada,et al.  uPARAP/Endo180 is essential for cellular uptake of collagen and promotes fibroblast collagen adhesion , 2003, The Journal of cell biology.

[53]  R. Aebersold,et al.  Mass spectrometry-based proteomics , 2003, Nature.

[54]  E. Lo,et al.  Blood-Brain Barrier Disruption and Matrix Metalloproteinase-9 Expression During Reperfusion Injury: Mechanical Versus Embolic Focal Ischemia in Spontaneously Hypertensive Rats , 2002, Stroke.

[55]  R. Powers,et al.  Impact of mobility on structure-based drug design for the MMPs. , 2002, Journal of the American Chemical Society.

[56]  A. Ben-Baruch.  Host microenvironment in breast cancer development: Inflammatory cells, cytokines and chemokines in breast cancer progression: reciprocal tumor–microenvironment interactions , 2002, Breast Cancer Research.

[57]  Carlos López-Otín,et al.  Strategies for MMP inhibition in cancer: innovations for the post-trial era , 2002, Nature Reviews Cancer.

[58]  C. Overall.  Molecular determinants of metalloproteinase substrate specificity , 2002, Molecular biotechnology.

[59]  J. Wallace,et al.  Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo. , 2002, Blood.

[60]  J. Nemunaitis,et al.  A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer , 2002, British Journal of Cancer.

[61]  C. López-Otín,et al.  Protease degradomics: A new challenge for proteomics , 2002, Nature Reviews Molecular Cell Biology.

[62]  J. Scholefield,et al.  Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial , 2002, British Journal of Cancer.

[63]  M. Washington,et al.  Matrix metalloproteinase-7 is expressed by pancreatic cancer precursors and regulates acinar-to-ductal metaplasia in exocrine pancreas , 2002 .

[64]  B. Fingleton,et al.  Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations , 2002, Science.

[65]  R. Bernards,et al.  A System for Stable Expression of Short Interfering RNAs in Mammalian Cells , 2002, Science.

[66]  Z. Werb,et al.  New functions for the matrix metalloproteinases in cancer progression , 2002, Nature Reviews Cancer.

[67]  K. Hess,et al.  Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[69]  C. Overall,et al.  Matrix Metalloproteinase Activity Inactivates the CXC Chemokine Stromal Cell-derived Factor-1* , 2001, The Journal of Biological Chemistry.

[70]  L. Matrisian,et al.  Matrix metalloproteinases: they're not just for matrix anymore! , 2001, Current opinion in cell biology.

[71]  C. Overall,et al.  Subcellular Distribution and Cytokine- and Chemokine-regulated Secretion of Leukolysin/MT6-MMP/MMP-25 in Neutrophils* , 2001, The Journal of Biological Chemistry.

[72]  S. Arii,et al.  Human macrophage metalloelastase gene expression in colorectal carcinoma and its clinicopathologic significance , 2001, Cancer.

[73]  T. Mcclanahan,et al.  Involvement of chemokine receptors in breast cancer metastasis , 2001, Nature.

[74]  S. Zucker,et al.  Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment , 2000, Oncogene.

[75]  D. Hanahan,et al.  MMP-9 Supplied by Bone Marrow–Derived Cells Contributes to Skin Carcinogenesis , 2000, Cell.

[76]  Shigeyoshi Itohara,et al.  Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis , 2000, Nature Cell Biology.

[77]  C. Overall,et al.  Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. , 2000, Science.

[78]  A. Burlingame,et al.  Epoxide electrophiles as activity-dependent cysteine protease profiling and discovery tools. , 2000, Chemistry & biology.

[79]  J. Drews.  Drug discovery: a historical perspective. , 2000, Science.

[80]  J. Ward,et al.  MT1-MMP-Deficient Mice Develop Dwarfism, Osteopenia, Arthritis, and Connective Tissue Disease due to Inadequate Collagen Turnover , 1999, Cell.

[81]  S. Gygi,et al.  Quantitative analysis of complex protein mixtures using isotope-coded affinity tags , 1999, Nature Biotechnology.

[82]  D. Hanahan,et al.  Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. , 1999, Science.

[83]  K. Shirato,et al.  Inhibition of matrix metalloproteinases prevents allergen-induced airway inflammation in a murine model of asthma. , 1999, Journal of immunology.

[84]  M. Mizumoto,et al.  Expression of human macrophage metalloelastase gene in hepatocellular carcinoma: Correlation with angiostatin generation and its clinical significance , 1998, Hepatology.

[85]  V. Kidd,et al.  Isolation and characterization of two novel metalloproteinase genes linked to the Cdc2L locus on human chromosome 1p36.3. , 1998, Genomics.

[86]  S. Itohara,et al.  Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. , 1998, Cancer research.

[87]  Thomas Boehm,et al.  Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance , 1997, Nature.

[88]  B. Hogan,et al.  Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[89]  D. Hanahan,et al.  Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.

[90]  J. Folkman,et al.  Angiostatin induces and sustains dormancy of human primary tumors in mice , 1996, Nature Medicine.

[91]  John E. Fothergill,et al.  Matrix metalloproteinase–1 is associated with poor prognosis in colorectal cancer , 1996, Nature Medicine.

[92]  Jack P. Witty,et al.  Decreased tumor formation in 7,12-dimethylbenzanthracene-treated stromelysin-1 transgenic mice is associated with alterations in mammary epithelial cell apoptosis. , 1995, Cancer research.

[93]  D. Hanahan,et al.  Progressive squamous epithelial neoplasia in K14-human papillomavirus type 16 transgenic mice , 1994, Journal of virology.

[94]  Linda M. Thienpont,et al.  Applications of isotope dilution-mass spectrometry in clinical chemistry, pharmacokinetics, and toxicology , 1992 .

[95]  P. Chambon,et al.  A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas , 1990, Nature.

[96]  C. Overall,et al.  Concanavalin A produces a matrix-degradative phenotype in human fibroblasts. Induction and endogenous activation of collagenase, 72-kDa gelatinase, and Pump-1 is accompanied by the suppression of the tissue inhibitor of matrix metalloproteinases. , 1990, The Journal of biological chemistry.

[97]  P. Waterhouse,et al.  Antisense RNA-induced reduction in murine TIMP levels confers oncogenicity on Swiss 3T3 cells. , 1989, Science.

[98]  L. Liotta,et al.  Metastatic potential correlates with enzymatic degradation of basement membrane collagen , 1980, Nature.

[99]  I. M. Neiman,et al.  [Inflammation and cancer]. , 1974, Patologicheskaia fiziologiia i eksperimental'naia terapiia.

[100]  C. Overall,et al.  Proteomic validation of protease drug targets: pharmacoproteomics of matrix metalloproteinase inhibitor drugs using isotope-coded affinity tag labelling and tandem mass spectrometry. , 2007, Current pharmaceutical design.

[101]  D. Morris,et al.  Randomised double blind placebo control study of adjuvant treatment with the metalloproteinase inhibitor, Marimastat in patients with inoperable colorectal hepatic metastases: significant survival advantage in patients with musculoskeletal side-effects. , 2003, Anticancer research.

[102]  Michael Williams.  Target validation. , 2003, Current opinion in pharmacology.

[103]  M. Lindsay.  Target discovery , 2003, Nature Reviews Drug Discovery.

[104]  B. Fingleton,et al.  Matrilysin [MMP-7] expression selects for cells with reduced sensitivity to apoptosis. , 2001, Neoplasia.

[105]  C. Sautès-Fridman,et al.  Metalloproteinase Host Mice Deficient for the Stromelysin-3 Matrix High Cancer Cell Death in Syngeneic Tumors Developed in Updated , 2001 .

[106]  K. Suzuki,et al.  Matrix metalloproteinases as insulin-like growth factor binding protein-degrading proteinases. , 1995, Progress in growth factor research.

[107]  Stetler-Stevenson Wg.  Progelatinase A activation during tumor cell invasion. , 1994 .

[108]  W. Stetler-Stevenson.  Progelatinase A activation during tumor cell invasion. , 1994, Invasion & metastasis.